Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04SLF
|
|||
| Former ID |
DCL000497
|
|||
| Drug Name |
Bevacizumab + Trastuzumab
|
|||
| Synonyms |
Lithocholic acid; LITHOCHOLIC ACID; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,
Click to Show/Hide
|
|||
| Drug Type |
Combination drug (Antibody)
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1] | |
| Company |
Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H40O3
|
|||
| Canonical SMILES |
CC(CCC(=O)O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C
|
|||
| InChI |
1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17-,18+,19-,20+,21+,23+,24-/m1/s1
|
|||
| InChIKey |
SMEROWZSTRWXGI-HVATVPOCSA-N
|
|||
| CAS Number |
CAS 434-13-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25. | |||
| REF 2 | Clinical pipeline report, company report or official report of Roche (2009). | |||
| REF 3 | Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.